We investigated the prognosis of patients with congestive heart failure (CHF) and the factors which influence the prognosis of Japanese patients with this condition. From among the patients admitted to our hospital from January 1, 1978 to December 31, 1985, the 298 patients who were diagnosed having CHF were investigated. Patients with CHF had a rather poor prognosis, with the 1-year, 3-year, and 5-year cumulative survival rates being 76% , 60% , and 49% , respectively. The factors influencing the prognosis of patients with CHF were the type of underlying heart disease, the left ventricular ejection fraction, the left ventricular end-diastolic dimension, and the central venous pressure. Survival rates differed significantly depending on the type of underlying heart disease. The cumulative 5-year survival rate was 35% for coronary artery disease, 40% for dilated cardiomyopathy, 53% for rheumatic valvular heart disease, and 80% for hypertensive heart disease. (Internal Medicine 31: 304-309, 1992) 
Introduction
Congestive heart failure (CHF) is a disorder with a high mortality rate and a 5 year survival rate of below 50% (1) . Numerous papers have been published con cerning the prognosis of patients with CHF in Western countries, but most of these have concentrated on CHF due to coronary artery disease (CAD) or dilated cardio myopathy (DCM). Moreover, such reports are still rare in the Japanese population. There are certain differences between the etiology of CHF in Japan and Western countries. Accordingly, this study was performed to clarify the prognosis of patients with CHF and the factors influencing it in the Japanese population. Methods
Patien ts
From among the patients admitted to our hospital (National Cardiovascular Center, Osaka, Japan) between January 1, 1978 and December 31, 1985, 298 consecutive patients (age ranging from 20-80 year) whose first or second diagnosis at discharge was CHF were selected for the study. Congestive heart failure was diagnosed based on the presence of subjective symptoms (dyspnea on exertion, paroxysmal nocturnal dyspnea, weight gain, leg edema) and/or the presence of cardiomegaly and pulmonary venous congestion on chest X-ray. Follow-up data were available for 282 patients, accounting for 95% of all the CHF patients. These included 90 patients with CAD, 55 patients with rheumatic valvular heart disease, 49 patients with hypertensive heart disease, 45 patients with DCM, 23 patients with non-rheumatic valvular heart disease, 8 patients with congenital heart disease (one patient with patent ductus arteriosus, 6 patients with atrial septal defect, and one patient with tetralogy of Fallot), and 12 patients with other types of heart disease. The other relevant demographic and clinical data are listed in Table 1 . All patients were in NYHA classes 2 to 4. The mean follow-up period was 40 months. Data Acquisition In December 1987, the status of all patients was surveyed using outpatient medical records and telephone interviews. The following factors were investigated; patient survival, cause of death, the result of cardiac Table 1 . Patient Background Data CAD: coronary artery disease, DCM: dilated cardiomyopathy, VHD: valvular heart disease, HHD: hypertensive heart disease, CHD: congenital heart disease, HT: hypertension, DM: diabetes mellitus, CRF: chronic renal failure, LVEF: left ventricular ejection fraction, LVDd: left ventricular end-diastolic dimension, CTR: cardiothoracic ratio, CVP: central venous pressure rence of the recurrent myocardial infarction and/or re admission for CHF. Parameters The duration of CHF was defined as the time interval from the onset of subjective symptoms (dyspnea on exertion, paroxysmal nocturnal dyspnea, orthopnea, and/or edema). Underlying disease was classified as congenital heart disease, rheumatic valvular heart disease , non-rheumatic valvular heart disease, DCM, CAD, hypertensive heart disease, and other heart diseases. DCM was diagnosed when no other cause of CHF was apparent after a full non-invasive and invasive work-up. Coronary artery disease was diagnosed by the demon stration of significant coronary artery stenosis (>70% ) and/or by electrocardiographs demonstration of prior myocardial infarction. Hypertensive heart disease was diagnosed when there was a history of hypertension, left ventricular hypertrophy demonstrated by electro cardiography or echocardiography, and lack of signs and symptoms of ischemic heart disease. The status of patients on admission was determined with respect to the following clinical parameters: heart rate, blood pressure, moist rales, hepatomegaly, and leg edema.
The data collected by various investigations included the detection of persistent atrial fibrillation, determination of the central venous pressure, assessment of the presence or severity of pulmonary venous congestion and the cardiothoracic ratio on chest X-ray, determination of the arterial oxygen partial pressure, and measurement of the left ventricular end-diastolic and end-systolic dimensions by echocardiography. All such data were obtained at the time of hospital admission or at the closest possible time to admission. The left ventricular ejection fraction was calculated from left ventriculography or radionuclide angiography after the symptoms of CHF had improved. Statistical analysis Analysis of survival after discharge from the hospital was based on life table methods. The generalized Wil coxon test was used for univariate analysis, and a p value of less than 0.05 was considered significant.
Results
Mo rta lity Twenty-four patients died during hospitalization and an additional 119 patients died during the follow-up period. Among them, 24 patients had sudden death (death within 1 hour of the onset of cardiovascular collapse). Figure 1 shows the cumulative survival rate for hospital survivors. Patients with symptomatic CHF had a poor prognosis, with the 1 year, 3 year, and 5 year survival rates being 76%, 60% , and 49% , respectively. Figure 2 shows the cumulative survival rate for patients with each type of underlying heart disease. The 5 year survival rates for DCM and CAD were 40% and 35%, respectively, while that for rheumatic valvular heart disease was 53% and that for hypertensive heart disease was 80%. Table 2 shows the results of the application of the generalized Wilcoxon test to parameters potentially influencing the total mortality rate. Parameters which significantly influenced the total mortality rate were the type of underlying heart disease, the left ventricular ejection fraction (LVEF), the left ventricular end diastolic dimension (LVDd), and the central venous pressure (CVP). Figure 3 shows the cumulative survival rates of patients with a CVP of less than and greater than 20 cm H2O. Figure 4 shows the cumulative survival rates of three groups of patients with different LVEF (an LVEF of less than 30%, 31-40%, and greater than 41%); the 3 year survival rates of these 3 groups were 50%, 59%, and 69% respectively. Figure 5 shows the cumulative survival rates of patients with a LVDd of less than 50mm, 51-60mm, or more than 61mm. Patients whose LVDd was more than 61mm had a significantly worse prognosis, with a 5 year survival rate of 41%.
There was no difference in the survival rate between the other 2 LVDd groups. There were some differences in the factors influencing the prognosis for each type of underlying heart disease ( Cumulative survival rates for patients with each type of underlying heart disease. CHD: congenital heart disease, VHD: valvular heart disease, DCM: dilated cardiomyopathy, CAD: coronary artery disease, HHD: hypertensive heart disease.
worse prognosis in younger patients) and LVEF were definite parameters, while the duration of symptomatic CHF (worse with longer duration), and the presence of atrial fibrillation also tended to worsen the prognosis. For CAD, the duration and grade of left heart failure were important factors. For rheumatic valvular heart disease, the duration of disease and a positive history of cardiac surgery were important, and an abnormal cardio thoracic ratio also tended to worsen the prognosis. 
Discussion
As part of the Framingham study, the natural history of patients with CHF was investigated over a 16 yeai period. The 1 year, 3 year, and 5 year survival rates were found tobe 79%, 55%, and 38% formen and 86%, 68%, and 57% for women, respectively (1 Tables 1 and 2. in two groups (a placebo group and a hydralazine-nitrate treatment group); the 1 year and 3 year survival rates were 80.5% and 53.1% in the placebo group and 87.9% and 63.8% in the hydralazine-nitrate group, respectively (5). Recently, vasodilator therapy combined with digitalis and diuretics has been widely used for the treatment of chronic CHF. In particular, angiotensin-converting enzyme inhibitor and the hydralazine-nitrate combi nation appear to be effective in improving the prognosis of patients with CHF (5, 6) . Almost all patients in the present study received digitalis and diuretics, while some were taking vasodilators such as isosorbide dinitrate, prazosin, and captopril. However, since our present study was performed retrospectively and the dose and duration of drug administration varied widely, it is difficult to reach any conclusions regarding their effectiveness.
Several older reports have suggested that elderly patients and male patients with CHF have a worse pro gnosis (1, 7, 8) . In the present study, however, age and gender showed no relationship to prognosis. Regarding the underlying heart diseases producing CHF, few reports have compared the prognosis for symptomatic hypertensive heart disease or rheumatic valvular heart disease with that for CAD or DCM. In unselected medically treated patients with mitral stenosis or mitral regurgitation of varying severity, the 5 year survival rate has previously been reported to be about 80% (8) . In patients with aortic stenosis, symptomatic CHF has a very poor prognosis without surgery, and the average survival period is said to be only 1.5 years (9) . Recently, the assessment of valvular stenosis and regurgitation has become easier with the widespread use of echocardiography and Doppler examination, with the result that patients with valvular heart disease can now be offered surgery at the optimum time. The present study showed that surgery is an important factor affecting the prognosis of valvular heart disease, with surgically treated patients having a better prognosis than those given medical treatment.
The present study showed that atrial fibrillation was associated with a worse prognosis in DCM, and similar results have been reported by other authors (10, ll significant risk factors in CHF (10) . Indices of left ventricular function, such as the ejection fraction, stroke work index, and left ventricular filling pressure are reported to be significant predictors of the prognosis in CHF (6, 10, (12) (13) (14) (15) (16) . We also found ejection fraction and left ventricular end-diastolic dimension to be major determinants of the prognosis. Several authors have reported that sudden death is common in patients with CHF and that the rate of sudden death varies from 30% to 45% (2, (15) (16) (17) (18) . Sudden death is usually thought to be attributed to the development of a fatal arrhythmias in such patients. Ambulatory electrocardiograph^ monitoring and in vasive electrophysiologic study are the main diagnostic tools available for detecting such life-threatening ar rhythmias, and may be useful to predict the prognosis in patients with CHF. In the present study, sudden death occured in 24 of 143 total deaths (17%), a lower rate than in the previous reports.
Limitations of the Present Study
The results of this study emphasize that underlying heart disease and easily obtainable clinical parameters can be applied to predict the prognosis of patients with CHF from the time of onset of their subjective symp toms requiring hospitalization. This study was done retrospectively in one national center hospital in Japan.
As a result, the number of patients was relatively small, and noninvasive and invasive studies were not uniformly performed on all study patients. Concerning the classifi cation of the underlying heart disease, we separated the diseases into only two subgroups of valvular heart disease (rheumatic and non-rheumatic), because the number of patients was limited. Since valvular heart disease is a very diverse clinical entity including stenosis and/or regurgitation of the mitral, aortic, tricuspid, and/or pulmonary valves, it is probably not adequate to divide it into only two groups. As previously mentioned, this study was performed retrospectively and we were not able to clarify the effectiveness of any specific drug treatment. Prospective and larger clinical studies will be needed to overcome these limitations.
In conclusion, patients with CHF were found to have a rather poor prognosis; the 1 year, 3 year, and 5 year survival rates were 76%, 60%, and 49%, respectively. The survival rates varied significantly according to the underlying heart disease producing CHF. Major factors influencing the prognosis of patients with CHF were the type of underlying heart disease, the left ventricular ejection fraction, the left ventricular end-systolic dimen sion, and the central venous pressure.
